These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8537139)

  • 41. Pharmacological properties of parenteral cephalosporins: rationale for ambulatory use.
    Strehl E; Kees F
    Drugs; 2000; 59 Suppl 3():9-18; discussion 47-9. PubMed ID: 10845409
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ceftibuten--a new oral cephalosporin.
    Med Lett Drugs Ther; 1996 Mar; 38(970):23-4. PubMed ID: 8598823
    [No Abstract]   [Full Text] [Related]  

  • 43. Symposium on antimicrobial therapy. IV. The cephalosporins.
    Greenfield RA
    J Okla State Med Assoc; 1993 Jan; 86(1):7-12. PubMed ID: 8426246
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of newer oral cephalosporins, fluoroquinolones, and macrolides in the treatment of pediatric infections.
    Rodriguez WJ; Wiedermann BL
    Adv Pediatr Infect Dis; 1994; 9():125-59. PubMed ID: 8123221
    [No Abstract]   [Full Text] [Related]  

  • 45. [Cedex (ceftibuten)--a 3rd-generation cephalosporin for internal use].
    Sidorenko SV
    Eksp Klin Farmakol; 1996; 59(3):64-71. PubMed ID: 8974589
    [No Abstract]   [Full Text] [Related]  

  • 46. In vitro activities of E1101, a novel oral cephalosporin, against bacteria causing infections in obstetric and gynecological patients.
    Mikamo H; Sato Y; Hayasaki Y; Kawazoe K; Tamaya T
    Chemotherapy; 1998; 44(5):328-30. PubMed ID: 9732148
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oral prodrug enters cephalosporin market.
    Thompson CA
    Am J Health Syst Pharm; 2001 Nov; 58(21):2018. PubMed ID: 11715819
    [No Abstract]   [Full Text] [Related]  

  • 48. In vivo antibacterial activity of FK041, a new orally active cephalosporin.
    Tawara S; Hatano K; Wakai Y; Matsumoto S; Watanabe Y; Matsumoto F; Kuwahara S
    J Antibiot (Tokyo); 1999 Jul; 52(7):660-5. PubMed ID: 10513846
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Role of parenteral cephalosporins for outpatients treatment of infections].
    Esposito S; Mazzei T; Novelli A
    Infez Med; 2001 Dec; 9(4):193-211. PubMed ID: 12087207
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten.
    Schatz BS; Karavokiros KT; Taeubel MA; Itokazu GS
    Ann Pharmacother; 1996 Mar; 30(3):258-68. PubMed ID: 8833562
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.
    Brogden RN; Spencer CM
    Drugs; 1997 Mar; 53(3):483-510. PubMed ID: 9074846
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Significant role of new oral cephem antibiotics. Focused on cefditoren pivoxil: discussion].
    Shimada K
    Jpn J Antibiot; 1994 Aug; 47(8):951-66. PubMed ID: 7933539
    [No Abstract]   [Full Text] [Related]  

  • 53. In vitro susceptibility of Helicobacter pylori to the new oral cephalosporins cefpodoxime, ceftibuten and cefixime.
    Westblom TU; Gudipati S; Midkiff BR
    Eur J Clin Microbiol Infect Dis; 1990 Sep; 9(9):691-3. PubMed ID: 2226500
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cefixime: an oral option for the treatment of multidrug-resistant enteric fever in children.
    Memon IA; Billoo AG; Memon HI
    South Med J; 1997 Dec; 90(12):1204-7. PubMed ID: 9404906
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative bioavailability of loracarbef chewable tablet vs. oral suspension in children.
    Abdel-Rahman SM; Blowey DL; Kauffmann RE; Kearns GL
    Pediatr Infect Dis J; 1998 Dec; 17(12):1171-3. PubMed ID: 9877373
    [No Abstract]   [Full Text] [Related]  

  • 56. Clinical and in vitro evaluation of cephapirin: a new parenteral cephalosporin.
    Bodner SJ; Koenig MG
    Am J Med Sci; 1972 Jan; 263(1):43-51. PubMed ID: 5057851
    [No Abstract]   [Full Text] [Related]  

  • 57. [Clinical studies on cefprozil granules in pediatrics].
    Nakazawa S; Sato H; Narita A; Nakazawa S; Suzuki H; Matsumoto K; Niinou K
    Jpn J Antibiot; 1992 Nov; 45(11):1514-25. PubMed ID: 1494234
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.
    Plosker GL; Foster RH; Benfield P
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):91-106. PubMed ID: 10175990
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Orally absorbable D-forphenicinol-cephalosporins.
    Koyama Y; Huang SP; Ikeda D; Hamada M; Kondo S; Takeuchi T
    J Antibiot (Tokyo); 1989 Jun; 42(6):993-9. PubMed ID: 2737957
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative in vitro activity of 5 cephalosporins with other antibiotics tested against 887 recent clinical isolates.
    Wasilauskas BL
    Chemotherapy; 1981; 27(6):416-22. PubMed ID: 7297171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.